Core Insights - Bonus Biogroup has appointed Professor Edwin M. Horwitz to its Advisory Board to strengthen its scientific leadership as it progresses toward Phase 3 clinical trials for its therapies BonoFill and MesenCure [1][2][3] Company Overview - Bonus Biogroup is a late-stage biotechnology company focused on immunomodulatory and regenerative mesenchymal stem cells (MSC) to develop innovative tissue engineering and cell therapy solutions [1][7] - The company aims to create effective and safe therapies for common and severe conditions with limited treatment options, ensuring broad accessibility through cost-effective solutions [7] Key Products BonoFill - BonoFill is an autologous tissue-engineered live human bone graft designed for treating large or nonhealing bone defects, with a 90% success rate in Phase 2 trials [4] - The company plans to initiate a Phase 3 study for BonoFill in 2026, targeting a total addressable market (TAM) of approximately $25.0 billion in the U.S. by 2030 [4] MesenCure - MesenCure is an allogeneic cell therapy aimed at treating inflammation and tissue damage, with a Phase 2 trial showing a 68% reduction in mortality for COVID-19 pneumonia patients [6] - The FDA has cleared an IND application for MesenCure, allowing the company to proceed with a Phase 3 clinical trial, with a market potential of approximately $9.4 billion in the U.S. by 2030 [6] Leadership and Expertise - Professor Horwitz brings over three decades of experience in cell therapy, clinical hematology, and oncology, enhancing the company's commitment to scientific excellence and innovation [2][3] - He has authored over 210 scientific publications, significantly influencing global research and therapeutic development in cell therapy [3] Intellectual Property - Bonus Biogroup holds a strong intellectual property portfolio with six patent families, including 71 granted patents and 10 pending applications across multiple countries [8]